This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from depression.
Randomised, double-blind, parallel-group trial in depressed adults with suicidal ideation comparing a single IV infusion of ketamine (0.5 mg/kg) versus midazolam (0.02 mg/kg); infusions administered over ~40 minutes.
Nonresponders who received midazolam may be offered a second ketamine infusion; participants receive weekly follow-up interviews for 6 weeks and may be offered standard antidepressant treatment thereafter. Study requires brief inpatient admission at NYSPI.
Single IV infusion of ketamine 0.5 mg/kg over ~40 minutes
IV infusion over ~40 minutes
Single IV infusion of midazolam 0.02 mg/kg over ~40 minutes (active comparator)
Midazolam 0.02 mg/kg IV over ~40 minutes (active comparator)
This double-blind, parallel-group trial (n=78) compared the effects of intravenous ketamine versus midazolam on neurocognition in depressed patients with significant suicidal ideation. While ketamine rapidly reduced suicidal ideation and improved reaction time and cognitive control, these neurocognitive improvements were independent of changes in depression or mood.